Because TET2 mutations change the HSPC balance in MPNs (6), we hypothesized that any advantage conferred by DNA methylation mutations in AML was partially due to expansion of more immature HSPCs, apparent as blasts. The gene discussed is TET2; the disease is acute myeloid leukemia.